Research programme: G protein-coupled receptor modulators - Arena Pharmaceuticals/TaiGen Biotechnology

Drug Profile

Research programme: G protein-coupled receptor modulators - Arena Pharmaceuticals/TaiGen Biotechnology

Alternative Names: GPCR modulators - Arena/TaiGen

Latest Information Update: 18 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TaiGen Biotechnology
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammation

Most Recent Events

  • 18 May 2007 Discontinued - Preclinical for Cancer in Taiwan (unspecified route)
  • 18 May 2007 Discontinued - Preclinical for Inflammation in Taiwan (unspecified route)
  • 01 Jul 2005 Arena Pharmaceuticals amends licensing agreement with TaiGen Biotechnology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top